

FAX this completed form to (877) 386-4695

OR Mail requests to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

I. PROVIDER INFORMATION		II. MEMBER INFORMATION	
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
Office Contact Name:		Group #:	
Group Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug request per form)			
Drug name and strength:		Dosage Interval (sig):	Qty. per Day & Duration:
IV. REQUIRED DOCUMENTATION (Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)			
Specify diagnosis & diagnosis code relevant to this request:		Dx/Dx Code: _____	
Requests for all non-preferred medications: Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Antibiotics, GI and Related Agents? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes <i>Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.</i> <input type="checkbox"/> No	
<input type="checkbox"/> If requesting for daily quantity exceeding daily limit (Refer to https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx), please provide supporting information: _____			
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.			
DIFICID (FIDAXOMICIN): <input type="checkbox"/> For the treatment of <i>Clostridioides difficile</i> infection (CDI), one of the following: <input type="checkbox"/> Has at least one of the following factors associated with a high risk of recurrence of CDI: <input type="checkbox"/> Age ≥65 years <input type="checkbox"/> Clinically severe CDI (Zar score ≥ 2): _____ <input type="checkbox"/> Is immunocompromised <input type="checkbox"/> Has a recurrent episode of CDI <input type="checkbox"/> Is prescribed Difacid (fidaxomicin) as a continuation of therapy upon inpatient discharge			
TRAVELERS' DIARRHEA: <input type="checkbox"/> History of therapeutic failure, contraindication or intolerance to Azithromycin (start date and end date): _____			
HEPATIC ENCEPHALOPATHY: <input type="checkbox"/> History of therapeutic failure, contraindication or intolerance to Lactulose: _____			
IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D): <input type="checkbox"/> Prescribed by or in consultation with a gastroenterologist ○ History of therapeutic failure to a low fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) diet: _____			

ZINPLAVA (BEZLOTOXUMAB):

- ☐ Prescribed by or in consultation with a gastroenterologist or infectious disease specialist
- ☐ Has a recent stool test positive for toxigenic *Clostridioides difficile*
- ☐ Has at least one of the following factors associated with a high risk for recurrence of *Clostridioides difficile* infection (CDI):
 - ☐ Age ≥65 years
 - ☐ Extended use of one or more systemic antibacterial drugs
 - ☐ Clinically severe CDI (Zar score ≥ 2): _____
 - ☐ At least one previous episode of CDI within the past 6 months or a documented history of at least 2 previous episodes of CDI
 - ☐ Is immunocompromised
 - ☐ The presence of a hypervirulent strain of CDI bacteria (ribotypes 027, 078, or 244)
- ☐ Is prescribed Zinplava (bezlotoxumab) in conjunction with an antibiotic regimen that is consistent with the standard of care
- ☐ Has not received a prior course of treatment with Zinplava (bezlotoxumab)

IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) RENEWAL REQUESTS:

- ☐ Member has experienced a successful initial treatment course
- ☐ Member has documented recurrence of IBS-D symptoms
- ☐ Member has not received 3 treatment courses with Xifaxan in lifetime

IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.

Provider Signature:

Date:

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)